公开(公告)号：US20240254441A1

公开(公告)日：2024-08-01

申请号：US18566518

申请日：2022-06-03

Applicant: KIRIN HOLDINGS KABUSHIKI KAISHA

Inventor： Shinichiro TAKAYANAGI ,  Ken FUKUMOTO

IPC: C12N5/078

CPC classification number: C12N5/0634 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2502/45

Abstract: An object of the present invention is to provide a technique for concentrating blood cells having high proliferation ability and/or differentiation ability. The present invention relates to a method for producing a cell composition, the method including: a step of extracting cells expressing a G protein-coupled receptor 56 (GPR56) from a cell aggregate containing immature blood cells, and a cell composition containing an immature blood cell expressing GPR56, in which a proportion of the immature blood cell expressing GPR56 is 50% to 100% of total cells.

公开(公告)号：US20240228977A1

公开(公告)日：2024-07-11

申请号：US18449100

申请日：2023-08-14

Applicant: FUJIFILM Cellular Dynamics, Inc.

Inventor： Amanda MACK

IPC: C12N5/074 ,  C12N15/85

CPC classification number: C12N5/0696 ,  C12N15/85 ,  C12N2500/98 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2506/11 ,  C12N2510/00

Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from peripheral blood cells, such as human blood progenitor cells, using episomal reprogramming and feeder-free or xeno-free conditions. In certain embodiments, the invention provides novel methods for improving overall reprogramming efficiency with low number of blood progenitor cells.

公开(公告)号：US11713447B2

公开(公告)日：2023-08-01

申请号：US16322584

申请日：2017-08-04

Applicant: Icahn School of Medicine at Mount Sinai

Inventor： Camelia Iancu-Rubin ,  Ronald Hoffman

IPC: C12N5/078 ,  A61K35/19

CPC classification number: C12N5/0644 ,  A61K35/19 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/999 ,  C12N2506/11

Abstract: The invention is directed to production of megakaryocyte (MK) compositions and their the treatment of thrombocytopenia in a subject in need thereof.

公开(公告)号：US20230159895A1

公开(公告)日：2023-05-25

申请号：US18057098

申请日：2022-11-18

Applicant: Fred Hutchinson Cancer Center

Inventor： Stefan Radtke ,  Hans-Peter Kiem ,  Jennifer E. Adair

IPC: C12N5/0789 ,  A61K35/28 ,  G01N33/569

CPC classification number: C12N5/0647 ,  A61K35/28 ,  G01N33/56972 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2510/00 ,  G01N2333/70589 ,  G01N2333/70596

Abstract: Strategies to assess and/or produce cell populations with predictive engraftment potential are described. The cell populations can be used for a variety of therapeutic and research purposes.

公开(公告)号：US20190231817A1

公开(公告)日：2019-08-01

申请号：US15772224

申请日：2016-10-28

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Gay M. CROOKS ,  Amélie MONTEL-HAGEN ,  Christopher SEET

IPC: A61K35/17 ,  C12N5/00 ,  C12N5/0783 ,  C12N5/074 ,  C12N5/0735 ,  C12N5/0775 ,  C12N5/077 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K2317/622 ,  C07K2319/03 ,  C12N5/00 ,  C12N5/0037 ,  C12N5/0062 ,  C12N5/0606 ,  C12N5/0636 ,  C12N5/0663 ,  C12N5/0669 ,  C12N5/0696 ,  C12N2500/22 ,  C12N2500/24 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/25

Abstract: Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.

公开(公告)号：US20190192691A1

公开(公告)日：2019-06-27

申请号：US16092829

申请日：2017-04-11

Applicant: Obsidian Therapeutics, Inc.

Inventor： Peter Barrett ,  Michael N. Gladstone ,  Tariq A. Kassum ,  Vipin Suri ,  Dan Jun Li ,  Dexue Sun ,  Brian Dolinski

IPC: A61K48/00 ,  A61K35/17 ,  A61P3/08 ,  C07K14/605 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0789 ,  C07K14/195 ,  C07K14/54 ,  C12N9/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725

CPC classification number: A61K48/0066 ,  A61K35/17 ,  A61K38/00 ,  A61P3/08 ,  C07K14/00 ,  C07K14/195 ,  C07K14/5428 ,  C07K14/5443 ,  C07K14/605 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  C12N5/0647 ,  C12N9/22 ,  C12N9/93 ,  C12N15/11 ,  C12N2310/20 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2316 ,  C12N2800/80 ,  C12Y603/04016

Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.

公开(公告)号：US20180214487A1

公开(公告)日：2018-08-02

申请号：US15745553

申请日：2016-07-20

Applicant: The Children's Medical Center Corporation

Inventor： Paolo Fiorina

IPC: A61K35/28 ,  C12N5/0789 ,  C07K14/705 ,  A61P3/10

CPC classification number: A61K35/28 ,  A61K2039/505 ,  A61P3/10 ,  C07K14/70532 ,  C07K16/2818 ,  C07K2317/75 ,  C12N5/0647 ,  C12N2500/90 ,  C12N2501/113 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/17 ,  C12N2501/91 ,  C12N2501/999 ,  C12N2510/00

Abstract: Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

公开(公告)号：US20180142212A1

公开(公告)日：2018-05-24

申请号：US15804555

申请日：2017-11-06

Applicant: Fred Hutchinson Cancer Research Center ,  NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS

Inventor： Irwin D. Bernstein ,  Anthony E. Boitano ,  Michael Cooke ,  Colleen Delaney

IPC: C12N5/0789 ,  A61K35/28

CPC classification number: C12N5/0647 ,  A61K35/28 ,  A61K2035/124 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/38 ,  C12N2501/42 ,  C12N2501/60 ,  C12N2501/999

Abstract: The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.

公开(公告)号：US20170335282A1

公开(公告)日：2017-11-23

申请号：US15672432

申请日：2017-08-09

Applicant: The Hospital for Sick Children

Inventor： Martin Post ,  Michael Litvack

IPC: C12N5/0786 ,  A61K35/15 ,  C12N5/0735

CPC classification number: C12N5/0645 ,  A61K35/15 ,  C12N5/0606 ,  C12N2500/90 ,  C12N2500/92 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/33 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

公开(公告)号：US09783783B2

公开(公告)日：2017-10-10

申请号：US14764346

申请日：2014-01-29

Applicant: CORNELL UNIVERSITY

Inventor： Pengbo Zhou

IPC: C07K14/47 ,  C12N5/0789 ,  A61K35/28

CPC classification number: C12N5/0647 ,  A61K35/28 ,  C07K14/47 ,  C07K14/4702 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2501/60

Abstract: The present disclosure relates to methods for expansion of stem cell populations using a polypeptide that enhances stem cell growth and proliferation. The present disclosure further relates to novel homeobox protein mutants (e.g., HOXA9 and HOXB4 mutant proteins) and the use thereof to expand certain stem cell populations. The present disclosure also provides methods for treating a subject in need of transplantation of stem cells.